PULMATRIX, INC. Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31)
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PULMATRIX, INC. development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for the quarter ending 2015-03-31 was $0.00.
- PULMATRIX, INC. development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for the quarter ending 2014-12-31 was $0.00.
- PULMATRIX, INC. development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for fiscal 2015 was $1.03M.
| Period end | Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31) 3 month | Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31) 12 month |
|---|---|---|
| 2015-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-06-10 | $1.03M 10-K · filed 2015-06-10 |
| 2014-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |